Retrospective analysis of cytology and high‐risk HPV testing in 1067 endocervical adenocarcinomas and precursor lesions
Cancer Cytopathology · 2024
DOI: 10.1002/cncy.22802 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cytopathology, 2024. Verfasst von Lei Ye und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Adenocarcinoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Background
Cytology and high‐risk human papilloma virus (hrHPV) cotesting is the mainstay in the detection of cervical carcinoma.
Methods
Endocervical adenocarcinoma (EAC) is divided into HPV‐associated adenocarcinoma (HPVA) and HPV‐independent adenocarcinoma (HPVI) by the World Health Organization classification (2020). The detection effect of cotesting is suggested to be different among EAC subtypes and precursors, but has not well‐documented yet. In this study, the authors retrospectively analyzed cotesting among adenocarcinoma in situ (AIS), HPVA, and HPVI. The cohort included 569 AIS and 498 EAC consisting of 371 (74.5%) HPVA, 111 (22.3%) HPVI, and 16 (3.2%) adenocarcinoma, not otherwise specified.
Results
The authors found that AIS patients were significantly younger than HPVA and HPVI (mean ± SD, years: 40.7 ± 8.6; HPVA, 44.8 ± 9.3; HPVI, 50.0 ± 11.3; p < .001) and had a higher prevalence of concurrent squamous intraepithelial lesions (75.5%, HPVA, 37.2%; HPVI, 12.6%; p < .001). The detection rate of hrHPV test or cytology was substantially higher in AIS and HPVA than in HPVI (97.7% and 90.2% vs. 16.5%, p < .001, or 71.1% and 71.9% vs. 60.7%, p = .042, respectively). Cytology and hrHPV cotesting was superior to a single test in the detection of EAC and AIS. The detection rate of cotesting amounted to 100% in AIS and 94.3% in HPVA but was substantially lower in HPVI (72.2%) ( p < .001).
Conclusions
The authors conclude that cytology and hrHPV cotesting can maximize the detection effect for HPVA and AIS but is not optimal for HPVI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
- Department of Surgical Pathology, Taizhou Hospital, Wenzhou Medical University, Taizhou, Zhejiang Province, China.
- Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
- Department of Surgical Pathology and Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Wo…
ORCID-Profile: Bingjian Lu
Zitieren
APA
Ye, L., Gan, M., Yao, Y., & Lu, B. (2024). Retrospective analysis of cytology and high‐risk HPV testing in 1067 endocervical adenocarcinomas and precursor lesions. Cancer Cytopathology. https://doi.org/10.1002/cncy.22802
Vancouver
Ye L, Gan M, Yao Y, Lu B. Retrospective analysis of cytology and high‐risk HPV testing in 1067 endocervical adenocarcinomas and precursor lesions. Cancer Cytopathology. 2024. doi:10.1002/cncy.22802
BibTeX
@article{Ye2024,
author = {Ye, Lei and Gan, Meifu and Yao, Yeli and Lu, Bingjian},
title = {Retrospective analysis of cytology and high‐risk HPV testing in 1067 endocervical adenocarcinomas and precursor lesions},
journal = {Cancer Cytopathology},
year = {2024},
doi = {10.1002/cncy.22802}
}
EUVIMED